Addex Therapeutics (ADXN)
NASDAQ:ADXN
Want to see ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
$8.23
$0.23(2.80%)
At close: 4:00 PM EST
$8.23
$0.23(2.80%)
Day’s Range― - ―
52-Week Range$5.41 - $12.05
Previous CloseN/A
Volume26.36K
Average Volume (3M)16.10K
Market Cap
$6.88M
Enterprise Value$5.38M
Total Cash (Recent Filing)$1.64M
Total Debt (Recent Filing)$34.73K
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Jun 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.10
Shares Outstanding1,822,121
10 Day Avg. Volume4,441
30 Day Avg. Volume16,099
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.20
Price to Sales (P/S)191.02
P/FCF Ratio-2.76
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue81.14
Enterprise Value/Gross Profit-32.02
Enterprise Value/Ebitda-0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.98
Revenue Forecast (FY)$1.79M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetThe company’s minimal leverage materially reduces financial risk and preserves strategic optionality. Low debt limits fixed obligations, extending operational flexibility while pursuing partnerships or selective R&D spend, and supports durability through funding cycles without immediate solvency pressure.
Very High Gross MarginsSustained gross margins near 95–100% indicate inherently favorable unit economics for the company’s drug-development outputs. If a candidate reaches commercialization or generates royalties, these margins support profitable scaling once operating expenses moderate, making gross margin a persistent structural strength.
Partnering-based Business ModelA partnering/licensing model reduces the need for large commercial infrastructure, enabling non-dilutive or milestone-driven cash inflows. Long-term, this model leverages big-pharma distribution and shifts commercialization risk, providing a durable route to revenue and de-risking scale requirements.
Bears Say
Persistent Negative Operating Cash FlowRecurring negative operating cash flow forces ongoing reliance on external financing, collaborations, or asset sales. Even with 2025 improvement, the company does not self-fund operations, raising structural risk of dilution or constrained R&D if partner payments or financings are delayed or unfavourable.
Deep, Loss-making OperationsExtremely negative operating and net margins reflect a business that is far from profitable and heavily dependent on non-operating items or occasional gains. This persistent unprofitability is a structural barrier to self-sustaining growth and elevates execution risk if revenue does not scale materially.
Volatile Equity / CapitalizationLarge swings in shareholders’ equity indicate prior dilution, episodic financing, or accumulated losses, reducing predictability of future capital structure. This volatility increases the probability of future dilutive raises or unfavorable funding terms, creating a recurring structural governance and financing risk.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $5.41 and its highest was $12.05 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $6.88M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Jun 15, 2026 which is in 11 days.
How were Addex Therapeutics’s earnings last quarter?
Currently, no data Available
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,822,121 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
ADXN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in key programs and strategic collaborations, which are positive indicators for future growth. However, the need for additional funding for unpartnered programs and stable but limited income suggest challenges in financial sustainability.View all ADXN earnings summariesTechnical Analysis
Kiora Pharmaceuticals
―
Xenetic Biosciences
―
Nucana
―
Creative Medical Technology Holdings
―
HCW Biologics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---